ASCO: Two-Year Survival Seen with Sutent in Kidney Cancer


http://... A. Figlin, M.D., City of Hope, Duarte, Calif.CHICAGO -- In patients with treatment-naive advanced renal cell carcinoma, treatment with sunitinib (Sutent) more than doubled progression-free survival compared with interferon alfa.







Channel: Education
Uploaded: June 11, 2008 at 8:34 am
Author: MedPageToday

Length: 00:01:59
Rating:
Views: 223

Tags: medicine health

Embed Code:


Video Comments:
No Comment
 

Privacy Policy Cancer Video | Treatment Survival & Education Copyright © 2007 All Rights Reserved.